@tom_luedde

Clinician scientist @UniklinikDUS. Working on molecular and clinical aspects of liver disease and GI cancer. Views are my own. #livertwitter

 Düsseldorf / Germany
Joined February 2017
  • Tweets523
  • Following1.4K
  • Followers1.5K
63Media
🔥off the press🔥 Cholangiocarcinoma 2026: status quo, unmet needs and priorities @NatRevGastroHep doi.org/10.1038/s41575-025-0… 👉get the lastest, most comprehensive summary on cholangiocarcinoma 👏fantastic team effort! @myESMO @EASLedu @ILCAnews
1
69
1
216
14,157
New online! Cholangiocarcinoma 2026: status quo, unmet needs and priorities bit.ly/4q14llS
2
94
5
275
32,486
Happy to share our review in Nat Rev Gastroenterol Hepatol on how regulated necrosis drives liver inflammation & HCC. Cell-specific roles,methodological advances, outstanding questionsand potential therapies—all summarized here! nature.com/articles/s41575-0… @NatRevGastroHep @EASLnews
3
12
1,478
Thanks for the invitation and the great discussions!
Hepatology Cima@Hepatology_Cima13 Nov 2025
Today we had the pleasure of hosting @tom_luedde  from @UniklinikDUS at @CIMA_unav who gave an excellent talk on “A decision point between cell death and transdifferentiation in carcinogenesis.” Thank you for sharing your research!
6
374
Had a great week at the Aegean Conference focused on Liver Diseases. Incredible presentations in the field and wonderful discussions. Lots of learning and a great time meeting with colleagues and new friends. #LiverDisease #AgeanConference #KalimeriKriti
1
7
527
Thrilled to share our new paper in @ScienceAdvances 🚀We uncover a new mechanism that protects adipocytes from cell death during #obesity and #ageing — with major implications for metabolic syndrome, including #diabetes, #MASLD and #lipodystrophy. science.org/doi/10.1126/scia…

Linear ubiquitination prevents lipodystrophy and obesity-associated metabolic syndrome

LUBAC preserves adipose tissue integrity via cell death inhibition, preventing metabolic disorders during aging and obesity.

science.org
3
8
2
20
4,146
Tom Luedde retweeted
EASLnews
@EASLnews18 Jul 2025
What are the latest and concrete recommendations for the clinical application of AI in hepatology?🤖 Read now this position paper from the EASL AI Task Force from @JHepatology: easl.eu/news/new-publication… #LiverX #LiverTwitter @JClusmann @C_V_Schneider @tpseraphin @tom_luedde @tom_marjot @AshleySpannMD @DebbieShawcros1 @SaSi_Lens @etrepo @jnkath
8
16
1,251
Tom Luedde retweeted
Mark Luedde@LuddeMark3 Jun 2025
SGLT2 inhibitors may be good for your heart in many ways. Here is one of them onlinelibrary.wiley.com/shar… @SamuelSossalla @UKGM @DiRudiger @J_Sedighi @tom_luedde @chris_sohns
2
3
1
7
869
Another great meeting coming up this year! aegeanconferences.org/src/Ap… @tom_luedde
2
1
321
Thanks to all speakers and the audience for a lively discussion! Fantastic opportunities for #ai but potential bias has to be considered and validation in trials needed! @EASLnews @EASLedu @HHU_de
EASL Education
@EASLedu8 May 2025
At #EASLCongress, experts explored how can #AI shape the future of liver cancer care: 🧬 Deep learning in histopathology & imaging 📈 LLMs in liver cancer prediction: breakthrough or illusion? ⚖️ Ethical implementation: the EASL way Key points on calibration, data quality & representation👇 @EASLnews #LiverX
2
2
20
2,714
We found that activating programmed necrosis through genetic or pharmacological interventions might be an effective anti-cancer-strategy in pancreatic cancer. Thanks to all collaborators and funders! @CancerInflam @HHU_de @MaxReichertMD nature.com/articles/s41467-0…
11
2
55
3,153
Thanks to all participants for a fantastic day of exciting Research! Thanks to @ReibergerThomas for your valuable Input and advice! @UniklinikDUS @MedHHU
Thomas Reiberger@ReibergerThomas15 Jan 2025
#LiverX Retreat of the FUTURE clinician scientist program - funded by DFG and coordinated by Prof @tom_luedde and Prof Michael Roden at Clinic Düsseldorf Great Research - personally biased interest for #BileAcid in Diastolic 🫀Dysfunction #Necroptosis in #MASH
15
1,082
>1000 participants in our Workshop GI Oncology ! Many innovations from 2024 are summarized in practical cases. Thanks to all speakers for a fantastic day! @UniklinikDUS @UKKoeln @UniklinikBonn @UniklinikAachen @UniklinikEssen @Krebshilfe_Bonn @DKG_Berlin
22
775
NAKO is the🇩🇪 equivalent of UK Biobank… funded by @BMBF_Bund. Unfortunately, the „# publications per € invested“ for NAKO is very low… The next government needs to make massive changes in @BMBF_Bund (other public funding initiatives are more successful, eg @BMG_Bund and @HorizonEU)
This Post is from an account that no longer exists. Learn more
2
6
27
4,801
Very proud of Christian Weigel who won the #dgvs teaching award for transforming teaching in Gastroenterology into the digital future. ⁦@HHU_de⁩ ⁦@MedHHU⁩ ⁦@DGVSJuGa⁩ ⁦@asta_hhu⁩
1
1
20
766
Thanks for the kind Invitation, very impressed by your and your colleagues‘ exciting Research in SFB TRR 353 @Uniklinik_Fr
Dhairya Rajguru@Dhairya_Rajguru25 Sep 2024
Excellent talk by @tom_luedde at @UniFreiburg on the cross talks of pathways followed by discussion on cell death & implications on cancer. It's exciting that scientists are working on understanding the phenomena I've always wanted to explore, and our thoughts align.
1
8
814
Fantastic start of the International Conference on Tropical Medicine and Global Health organized by our very own Torsten Feldt and team. >500 participants from all over the world. @UniklinikDUS @HHU_de @DGVSJuGa @junite_e @UKKoeln thanks to all who helped and supported
2
7
638
Universität Düsseldorf: Leberkrebs: Die Fitness von Tumorzellen als Angriffspunkt für neue Therapien medizin.hhu.de/news-detailin…

Aktuelle Publikation im Journal of Hepatology

Leberkrebs ist eine schwerwiegende Erkrankung, die nur bei einem Teil der Patientinnen und Patienten geheilt werden kann, wenn sie frühzeitig erkannt wird. Glücklicherweise wurden in den letzten...

medizin.hhu.de
1
14
1,097
Out in @JHepatology : KIF23 and miR-107 control replicative fitness in hepatocellular carcinoma and might be a new therap. target. Thanks to all collaborators and funders! journal-of-hepatology.eu/art… @EASLedu @EASLnews @MedHHU @UniklinikDUS @CancerInflam @dfg_public @IfADo_info
6
1
48
4,798
Excited to share our aMASLDing research on how machine learning uncovered dietary manganese might protect against hepatic steatosis. #LiverHealth #MASLD (1/10) @ktc_phd @KM_Schneider1 @JClusmann @DrLoomba @tom_luedde onlinelibrary.wiley.com/doi/…

Machine learning uncovers manganese as a key nutrient associated with reduced risk of steatotic...

Background Metabolic dysfunction-associated steatotic liver disease (MASLD) affects approximately 20%–30% of the general population and is linked to high-caloric western style diet. However, there...

onlinelibrary.wiley.com
3
4
2
46
3,563
Load more